Home » Archive

Articles in the Clinical Research Category

Basic Research, Clinical Research, Headline »

[2 Oct 2014 | No Comment | 1,780 views]
Germline Mutation of Bap1 accelerates the development of asbestos-induced malignant mesothelioma

In the current study, Dr. Testa and his team at Fox Chase exposed mice with and without BAP1 mutations to asbestos, and they also followed a group of unexposed mutant mice to see if they developed any cancers.

By the end of the study, 73% of mutated mice exposed to asbestos had developed mesothelioma, compared to only 32% of exposed mice that did not carry any BAP1 mutation. In the mutant mice, the mesotheliomas appeared sooner, and were more aggressive, as well.

None of the unexposed mice that carried a BAP1 mutation developed mesothelioma after up to 87 weeks of follow-up, although one was diagnosed with a tumor of breast tissue origin.

Basic Research, Clinical Research, Uncategorized »

[16 Sep 2014 | No Comment | 5,126 views]
Macrophage phenotypes ratio is a prognostic factor in malignant pleural mesothelioma.

Macrophages are the dominant leukocyte population found in the tumor microenvironment. Accumulating evidence suggests that these tumor-associated macrophages (TAMs) actively promote all aspects of tumor initiation, growth, and development.

However, TAMs are not a single uniform population; instead, they are composed of multiple distinct pro- and anti-tumoral subpopulations with overlapping features depending on a variety of external factors. M1 skewed macrophages possess anti-tumoral capacities, while the M2 polarized macrophages have pro-tumoral capacities.

Clinical Research, Headline »

[26 Nov 2013 | No Comment | 6,716 views]
An Anti-CTLA4 antibody may be effective in malignant mesothelioma

Recent studies have indicated that tumor-specific immune responses may be activated in patients with malignant mesothelioma, suggesting that inhibition of the immunosuppressive receptor cytotoxic T-lymphocyte-associated protein 4 (CTLA4) may enhance antitumor T-cell activity.

Calabrò and colleagues performed an open-label, single-arm phase II trial to investigate the safety and efficacy of tremelimumab, a monoclonal antibody related to ipilimumab that targets CTLA4, in 29 patients with unresectable malignant melanoma who had previously received platinum-based therapy.

Clinical Research, Videos / Lectures »

[29 Aug 2013 | No Comment | 3,879 views]
Annals of Cardiothoracic Surgery: Mesothelioma

Many leading investigators have contributed to the November 2012 issue of Annals Of Cardiothoracic Surgery to provide an overview of the state of the art in translational research and clinical care in malignant pleural mesothelioma.

In addition to chapters that highlight various areas such as epidemiology, biomarkers, prognostic factors and multimodality therapy, videos showing the techniques for extended pleurectomy/ decortication and extrapleural pneumonectomy are included.

Basic Research, Clinical Research »

[10 May 2013 | One Comment | 27,647 views]
A new way of looking at cancer is on its way

The progression and evolution of cancer genomics is giving us unprecedented insight into malignancies. Most recently, a paper on acute myeloid leukemia and one on endometrial carcinoma, part of an ambitious project by the National Institutes of Health to scrutinize DNA aberrations in common cancers, have highlighted that cancer will increasingly be seen as a disease defined by its genetic fingerprint rather than by the organ where it originated.

Basic Research, Clinical Research »

[8 Apr 2013 | No Comment | 5,473 views]
Sequential Binary Gene-Ratio: a novel molecular diagnostic strategy

Though long considered the gold-standard for diagnosing cancer, customary pathological approaches are not always successful.

Here, De Rienzo and colleagues applied the bioinformatic technique of gene-expression ratio tests to develop and validate molecular signatures for the differential diagnosis of mesothelioma (MPM) as proof of principle of the applicability of this technique to cancer diagnosis.

Asbestos, Basic Research, Clinical Research »

[29 Nov 2012 | No Comment | 7,531 views]
Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool

Early detection of mesothelioma is key for chemo-efficiency. The authors conducted a multi-center case-control studies in serum from 117 mesothelioma cases and 142 asbestos-exposed control individuals. Biomarker discovery, verification, and validation were performed using the SOMAmer proteomic technology, which simultaneously measures over 1000 proteins in unfractionated biologic samples. Using univariate and multivariate approaches they discovered 64 candidate protein biomarkers, consisting of both inflammatory and proliferative proteins, processes strongly associated with asbestos-induced malignancy. The author further selected a pool of 13 candidate proteins (classifiers) for distinguishing mesotheliomas from controls. The ability of the classifiers …

Clinical Research, iMig conferences »

[4 Sep 2012 | 3 Comments | 9,026 views]
Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group

This publication represents an update to the iMig guidelines that were first published in 2009, following the iMig meeting held in Chicago (Oct. 2006). This update is meant to be a practical guide for pathologists and presents consensus views on diagnosis and the common pitfalls to be avoided.

Basic Research, Clinical Research »

[2 May 2012 | No Comment | 1,424 views]
MARF 2012 Grant Program – Call for Applications

The Mesothelioma Applied Research Foundation is calling for applications for its 2012 round of mesothelioma research grant funding. Continuing its efforts to stimulate translational research for the treatment of malignant mesothelioma, the Meso Foundation is again soliciting applications for funding of innovative projects that address issues for the treatment of the disease.

Clinical Research »

[26 Mar 2012 | 2 Comments | 5,228 views]
Serum mesothelin for diagnosing malignant pleural mesothelioma

Mesothelin is currently considered the best available serum biomarker for malignant pleural mesothelioma. To examine the reported diagnostic accuracy of mesothelin and evaluate its value for early diagnosis, the authors performed a meta-analysis on the individual patient data (IPD) of 16 diagnostic studies, representing a total of 4,491 individuals, including 1,026 patients with malignant pleural mesothelioma.
They found a significant heterogeneity in reported diagnostic accuracies of mesothelin (see Figure for sensitivity of mesothelin in different studies). Differences in study population can explain this heterogeneity, since the type of control group, mesothelioma …